Evolve BioSystems is dedicated to developing the next generation of products to establish, restore, and maintain a healthy newborn gut microbiome.
Building on a decade of expertise in the partnership between the infant gut microbiome and human breast milk, Evolve is solving newborn gut dysbiosis, or an imbalance of beneficial bacteria, through microbiome-based interventions in both human and animal health.
On Oct. 2nd, Dr. David Kyle, Chairman and Chief Science Officer of Evolve BioSystems, will be the keynote speaker, presenting: From Dysbiosis to Recovery in the Infant Gut Microbiome: A new Paradigm in Infant Nutrition.
Vienna, Austria (Sept. 22, 2017): Dr. David Kyle, Chairman and Chief Science Officer of Evolve BioSystems, will present: Rescuing the Infant Gut Microbiome.
Come visit us at booth #576! Evolve BioSystems is proud to participate in the American Academy of Pediatrics national conference in Chicago, Sept. 16-19.
Evolve BioSystems, Inc. has appointed Timothy B. Brown as CEO, effective August 1, 2017, while Dr. David J. Kyle, the Company's current CEO, will assume the new role of Executive Chairman of the Board and active Chief Scientific Officer.
Evolve BioSystems is proud to participate in Hambletonian Festival Week, taking place August 3rd-5th at Meadowlands Racetrack, E. Rutherford, New Jersey.
Evivo is the Only Probiotic Clinically Proven to Restore Baby’s Gut Microbiome
Evolve BioSystems, Inc. announces the introduction of Evivo, the first and only probiotic clinically proven to restore a baby’s gut microbiome to its original, natural state. Once-daily Evivo helps develop a healthy immune system and metabolism to set up babies for healthier lives.
Evolve BioSystems announced today that it has completed a $20 million Series B financing to fund the commercialization of its initial infant health products.
Come join Evolve as we enjoy the Devon Horse Show, and to learn how our animal health product, GlycoGuard® supports a healthy gut microbiome in nursing foals.